Publications by authors named "C V Verghese"
Article Synopsis
- Immune checkpoint inhibitors (CPIs) can lead to rare but serious immune-related adverse effects, such as immune-related autoimmune hemolytic anemia (irAIHA), which complicates diagnosis due to overlapping symptoms with other treatments.
- Diagnosis involves ruling out other causes of anemia and treatment varies based on severity, with lower grades managed supportively and higher grades often requiring cessation of therapy or aggressive treatment.
- For grade 4 irAIHA linked to PD-1 blockers like pembrolizumab, a specific treatment protocol is suggested, often beginning with corticosteroids and potentially leading to alternative immunosuppressive therapies if steroids fail.
Splenic lymphoma may be primary or secondary. Primary splenic lymphoma's are rare and usually of follicular cell origin representing <1% of Non-Hodgkin's Lymphoma's. Most are secondary with 35% representing Marginal Cell sub-type with the rest being Diffuse Large B-Cell Lymphoma's.
View Article and Find Full Text PDFArticle Synopsis
- * A study analyzed healthcare data to explore how age influences the development of VTE in lung cancer patients, finding that younger patients (under 65) had more occurrences of various types of VTE compared to older patients.
- * Specifically, patients under 65 experienced significantly higher rates of pulmonary embolism and other VTE types, indicating that younger cancer patients may need targeted monitoring and prevention strategies.
Background: Individuals with tardive dyskinesia (TD) who completed a long-term study (KINECT 3 or KINECT 4) of valbenazine (40 or 80 mg/day, once-daily for up to 48 weeks followed by 4-week washout) were enrolled in a subsequent study (NCT02736955) that was primarily designed to further evaluate the long-term safety of valbenazine.
Methods: Participants were initiated at 40 mg/day (following prior valbenazine washout). At week 4, dosing was escalated to 80 mg/day based on tolerability and clinical assessment of TD; reduction to 40 mg/day was allowed for tolerability.